Clinical Trials Browser

Phase 2 × Rectal Cancer Patients × Radiotherapy × Clear all

NCT07291401 2025-12-18

Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Cancer Patients